Mar 05th 2013 - Edison Investment Research today published a report on Sucampo Pharmaceuticals entitled "Competitive Footing For Rescula". In summary, the report says:
Sucampo’s launch of glaucoma drug Rescula onto the US market is its first self-commercialisation effort. Careful product positioning and a targeted commercial campaign, emphasising Rescula’s novel mode of action, should give the drug a competitive foothold in a highly competitive market. The wholesale acquisition cost (WAC) of $99 per script (30-day eye drop supply) is on a par with some branded prostaglandins (Zioptan) and is higher than our previous price assumption. We raise our peak US sales estimate for Rescula to $90m (previously $65m) and increase our valuation of Sucampo to $335m or $8.00 per share (vs $315m, $7.52 per share).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »